Observational studyMedicine2025
Association between neutrophil to high-density lipoprotein ratio and no-reflow after coronary intervention: A cross-sectional study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory responses and lipid metabolism disorders are key components in the development of coronary artery disease and contribute to no-reflow after coronary intervention. This study aimed to investigate the association between the neutrophil to high-density lipoprotein ratio (NHR) and no-reflow phenomenon in ST-segment elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention (PPCI). This study enrolled 288 patients with STEMI from September 1st, 2022 to February 29th, 2024, in the Zhengzhou Central Hospital Affiliated to Zhengzhou University. According to postoperative thrombolysis in myocardial infarction flow grades, there were 221 patients in the normal flow group and 67 patients in the no-reflow group. Comparing the clinical data of the 2 groups, the independent risk factors of no-reflow phenomenon in STEMI patients after PPCI were determined by multivariate logistic regression analysis. Additionally, we assessed the diagnostic value of NHR for no-reflow using receiver operating characteristic curve analysis. The no-reflow phenomenon was observed in 67 patients with STEMI following PPCI, representing a prevalence of 23.26%. Compared with the normal group, NHR, as well as the rates of intracoronary thrombolysis and thrombus aspiration, were significantly elevated, while lymphocyte and albumin were lower (P < .05). Multivariate logistic regression analysis revealed that NHR was an independent risk factor for no-reflow (OR = 1.241, 95% CI: 1.142-1.349, P < .001). In the receiver operating characteristic curve of NHR diagnosis of no-reflow, the area under the curve (AUC) was 0.740 (95% CI: 0.671-0.809, P < .001), and the optimal critical value was 7.88, which indicates sensitivity and specificity were 71.6% and 71.50%. NHR may serve as a risk mark for STEMI patients with no-reflow after PPCI, and has diagnosis value for its occurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.